Clinical Trials Logo

Biliary Tract Tumor clinical trials

View clinical trials related to Biliary Tract Tumor.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06048289 Recruiting - Cholangiocarcinoma Clinical Trials

Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy

Start date: September 14, 2023
Phase:
Study type: Observational

A prospective, observational study to explore multidimensional biomarkers for predicting the efficacy of immunotherapy In biliary tract tumors

NCT ID: NCT05291052 Recruiting - Biliary Tract Tumor Clinical Trials

Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors

Start date: February 14, 2022
Phase: Phase 2
Study type: Interventional

This study is a single-center, single-arm, open-label clinical study. All patients with advanced and unresectable biliary tract tumors will be treated with the combination of tisleizumab, lenvatinib and XELOX regimen (oxaliplatin plus capecitabine) until disease progression , unacceptable toxicity, death or the patient meets any other discontinuation criteria described in the protocol, whichever occurs first. Subjects can receive up to 8 cycles of the XELOX regimen. For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years. Patients will be closely monitored for safety and tolerability throughout the study.